Evaluation of the association between platelet tests and thyroid-stimulating hormone levels in patients with vitiligo

Basit Öğe Kaydı
dc.contributor.authorAksoy Sarac, Gulhan
dc.contributor.authorIbis, Saadet
dc.contributor.authorAkdag, Turan
dc.date.accessioned2024-02-23T14:24:30Z
dc.date.available2024-02-23T14:24:30Z
dc.date.issued2022
dc.departmentNEÜen_US
dc.description.abstractObjective Vitiligo is a common dermatological disease of unknown cause and progressing with depigmentation and affects approximately 1% of the world population. In the study, we aimed to compare plateletcrit (PCT), mean platelet volume (MPV), platelet (PLT), and thyroid-stimulating hormone (TSH) values in vitiligo patients. Material and Methods We retrospectively evaluated the medical data of 100 patients who were admitted to the dermatology outpatient clinic between January 2020 and December 2021 with a diagnosis of vitiligo. The control group was retrospectively constituted from medical records of 90 healthy individuals. PCT, MPV, PLT, and TSH levels of both groups were compared statistically. Results A total of 190 participants (100 vitiligo patients and 90 healthy volunteers) were included in the study. The mean age of the patient group was 38.62 +/- 1.62, while the mean age of the control group was 41.52 +/- 1.54. There were no differences between the two groups in terms of age and gender. It was found that the mean MPV value in the patient group was lower than the control group (p = 0.00). PLT and PCT values were significantly higher in the patient group than the control group (p = 0.00, p = 0.01, respectively). There was no statistically significant difference between the two groups in terms of TSH (p > 0.05). A negative correlation between MPV and PLT values in the patient group (r = -0.218, p = 0.029), and a negative correlation between MPV and TSH (r = -0.218, p = 0.029), (-0.230, p = 0.021). Conclusion In the study, a comparison of the PCT, MPV, and PLT levels showed a difference between both groups, but no differences in TSH levels. To clarify these results, comprehensive studies with more samples are needed.en_US
dc.identifier.doi10.1111/jocd.14848
dc.identifier.endpage3597en_US
dc.identifier.issn1473-2130
dc.identifier.issn1473-2165
dc.identifier.issue8en_US
dc.identifier.pmid35156762en_US
dc.identifier.scopus2-s2.0-85125056212en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage3593en_US
dc.identifier.urihttps://doi.org/10.1111/jocd.14848
dc.identifier.urihttps://hdl.handle.net/20.500.12452/13968
dc.identifier.volume21en_US
dc.identifier.wosWOS:000759599500001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofJournal Of Cosmetic Dermatologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectPlateletsen_US
dc.subjectThyroid Functionsen_US
dc.subjectVitiligoen_US
dc.titleEvaluation of the association between platelet tests and thyroid-stimulating hormone levels in patients with vitiligoen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu